clinical trial · NCT07843641
A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal NeoplasmsVelzatinib
brief summary
This study aims to evaluate the long-term safety and tolerability of velzatinib (GSK6042981) in adults with GIST who have previously received velzatinib in parent study and continue to benefit from the treatment. Participants will be monitored for side effects and overall health to better understand the effects of long-term treatment and support future care for adults with GIST.
started
Oct 13, 2026
primary completion
Jan 31, 2031
completion
Jan 31, 2031
last updated
Sep 28, 2026
official title
A Phase 2, StrateGIST Legacy Study to Provide Continued Treatment With Velzatinib to Participants With Gastrointestinal Stromal Tumors (GIST) Who Have Completed a Velzatinib Parent Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol